Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Society for Medical Oncology

Patient-Reported Outcomes From AMPLITUDE, a Randomized, Placebo-Controlled Phase 3 Trial of Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Hormone-Sensitive Prostate Cancer With Homologous Recombination Repair Mutations

CARVYKTI_US-SR-10459

CARVYKTI_US-SR-10545

Test-EL

Carvykti Dossier banner

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

akeega

Dark Blue

oncology

patient-reported-outcomes-from-amplitude

Whitelist Modal

Patient-Reported Outcomes From AMPLITUDE, a Randomized, Placebo-Controlled Phase 3 Trial of Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Hormone-Sensitive Prostate Cancer With Homologous Recombination Repair Mutations

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join